INDEMNIFICATION AGREEMENTIndemnification Agreement • October 24th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of , 2014 by and between Coherus BioSciences, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
COHERUS BIOSCIENCES, INC. [ ] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 24th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
Coherus BioSciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
AMENDMENT #3 TO TASK ORDER #20 COHERUS Project Number: CHS-0214-04 MEDPACE Project Number: ETA304Coherus BioSciences, Inc. • October 24th, 2014 • Biological products, (no disgnostic substances)
This Amendment #3 (“Amendment #3”) to Task Order #20 effective as of November 8, 2013 (“Task Order”), is by and between Coherus Biosciences, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc., with its principal place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #3 shall be effective September 5, 2014.
AMENDMENT #1 TO TASK ORDER #20 COHERUS Project Number: CHS-0214-04 MEDPACE Project Number: ETA304Coherus BioSciences, Inc. • October 24th, 2014 • Biological products, (no disgnostic substances)
CONFIDENTIALCoherus BioSciences, Inc. • October 24th, 2014 • Biological products, (no disgnostic substances)
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
